ADRO - アデュロ・バイオテック (Aduro Biotech Inc.) アデュロ・バイオテック

 ADROのチャート


 ADROの企業情報

symbol ADRO
会社名 Aduro Biotech Inc (アデュロ・バイオテック)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アデュロ・バイオテク(Aduro BioTech Inc)は癌を含む各種の疾患の治療法の発見・開発・商業化に従事する免疫療法会社である。同社の製品候補は、ライブ、弱毒化、二重欠失(LADD)リステリアモノサイトゲネス、インターフェロン遺伝子経路経路活性化因子の刺激、及びB-選択モノクローナル抗体プラットフォームからのものであり、単一の薬剤として、または従来の治療法と組み合わせて、及び他の免疫療法として、自然免疫応答および適応免疫応答を刺激および/または調節するように設計されている。LADD技術プラットフォームは、中皮腫、卵巣癌、胃癌、肺癌および前立腺癌を含む複数の適応症の治療薬として開発されている。LADD製品候補は、中皮腫、卵巣癌および胃癌を含む複数の適応症の治療薬として開発されているCRS-207である。ADU-214とADU-741は、肺癌と前立腺癌の開発候補製品である。   アデュロ・バイオテックは、米国のバイオ医薬品会社。癌に対する免疫応答を刺激するために設計された技術プラットフォ―ムの開発に焦点を当て、腫瘍細胞の成長と普及を遅らせる、または排除するために患者の免疫系に影響を与える治療法の開発に従事。主要製品として、転移性膵臓癌と切除不能悪性胸膜中皮腫の治療用LADD製品であるCRS-207を提供する。   Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
本社所在地 740 Heinz Avenue Berkeley CA 94710 USA
代表者氏名 Stephen T. Isaacs スティーブン・T・アイザックス
代表者役職名 Chairman of the Board President and Chief Executive Officer
電話番号 +1 510-848-4400
設立年月日 2000年
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 162人
url www.aduro.com
nasdaq_url https://www.nasdaq.com/symbol/adro
adr_tso
EBITDA EBITDA(百万ドル) -100.80240
終値(lastsale) 6.09
時価総額(marketcap) 481473962.76
時価総額 時価総額(百万ドル) 515.46970
売上高 売上高(百万ドル) 16.81600
企業価値(EV) 企業価値(EV)(百万ドル) 226.35770
当期純利益 当期純利益(百万ドル) -93.14300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aduro BioTech Inc revenues decreased 4% to $9.3M. Net loss increased 11% to $45.9M. Revenues reflect Grant revenue decrease from $41K to $0K. Higher net loss reflects General and administrative. - other increase of 6% to $13.9M (expense) Stock-based Compensation increase of 15% to $5.3M (expense) Stock-based Compensation increase of 17% to $4M (expense).

 ADROのテクニカル分析


 ADROのニュース

   Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results  2020/08/03 20:05:00 GlobeNewswire
BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing…
   Aduro Biotech's Shares March Higher, Can It Continue?  2020/05/26 12:11:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Aduro Biotech.
   Aduro Biotech (ADRO) Upgraded to Buy: What Does It Mean for the Stock?  2020/05/25 16:00:05 Zacks Investment Research
Aduro Biotech (ADRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Is Aduro Biotech (ADRO) Stock a Solid Choice Right Now?  2020/05/11 12:35:00 Zacks Investment Research
Aduro Biotech (ADRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Aduro Biotech (ADRO) Down 3.1% Since Last Earnings Report: Can It Rebound?  2020/04/08 15:30:07 Zacks Investment Research
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Aduro Biotech's Shares March Higher, Can It Continue?  2020/05/26 12:11:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Aduro Biotech.
   Aduro Biotech (ADRO) Upgraded to Buy: What Does It Mean for the Stock?  2020/05/25 16:00:05 Zacks Investment Research
Aduro Biotech (ADRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Is Aduro Biotech (ADRO) Stock a Solid Choice Right Now?  2020/05/11 12:35:00 Zacks Investment Research
Aduro Biotech (ADRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Aduro Biotech (ADRO) Down 3.1% Since Last Earnings Report: Can It Rebound?  2020/04/08 15:30:07 Zacks Investment Research
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Has Aduro Biotech (ADRO) Outpaced Other Medical Stocks This Year?  2020/04/01 16:05:32 Zacks Investment Research
Is (ADRO) Outperforming Other Medical Stocks This Year?
   Is Aduro Biotech (ADRO) Stock Outpacing Its Medical Peers This Year?  2020/02/28 16:30:10 Zacks Investment Research
Is (ADRO) Outperforming Other Medical Stocks This Year?
   Aduro Biotech (ADRO) Up 7.5% Since Last Earnings Report: Can It Continue?  2019/12/07 16:31:14 Zacks Investment Research
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave  2019/09/27 11:56:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 26.) AstraZeneca plc (NYSE: AZN ) GlaxoSmithKline plc (NYSE: GSK ) Sanofi SA (NASDAQ: SNY ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (announced submission of clinical trial application to U.K. regulators for its investigational therapy for phenylketonuria) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) strong>DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) ( announced mid-stage results of NASH treatment candidate) Enochian Biosciences Inc (NASDAQ: ENOB ) Erytech Pharma SA (NASDAQ: ERYP ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Gritstone Oncology Inc (NASDAQ: GRTS ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) IGM Biosciences Inc (NASDAQ: IGMS ) (initial public offering on Sept.
   The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug  2019/09/25 11:13:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 24) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Celgene Corporation (NASDAQ: CELG ) Natera Inc (NASDAQ: NTRA ) Sanofi SA (NASDAQ: SNY ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL )(announced positive results for the pediatric Phase 3 trial of dasiglucagon for severe hypoglycemia in diabetes) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 24) Aduro BioTech Inc (NASDAQ: ADRO ) Advaxis, Inc. (NASDAQ: ADXS ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) AnaptysBio Inc (NASDAQ: ANAB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) Clovis Oncology Inc (NASDAQ: CLVS ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Endologix, Inc. (NASDAQ: ELGX ) Erytech Pharma SA (NASDAQ: ERYP ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Fulcrum Therapeutics Inc (NASDAQ: FULC Innoviva Inc (NASDAQ: INVA ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Myovant Sciences Ltd (NYSE: MYOV ) Neon Therapeutics Inc (NASDAQ: NTGN ) Onconova Therapeutics Inc (NASDAQ: ONTX ) ProQR Therapeutics NV (NASDAQ: PRQR ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) (priced its IPO on Sept. 13) Seelos Therapeutics Inc (NASDAQ: …
   The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger  2019/09/24 12:12:30 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) ( announced a communication from the FDA allowing it to proceed with a reduced sample size in a Phase 3 study of its drug to treat excessive daytime sleepiness) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Celgene Corporation (NASDAQ: CELG ) Cesca Therapeutics Inc (NASDAQ: KOOL ) DURECT Corporation (NASDAQ: DRRX ) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) Sanofi SA (NASDAQ: SNY ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 23) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) (announced departures of CEO, president and COO, and the appointment of board member Damien McDevitt as interim CEO) BioNano Genomics Inc (NASDAQ: BNGO ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) Clovis Oncology Inc (NASDAQ: CLVS ) (announced acquisition of rights to FAP-targeted radiopharmaceuticals from 3B Pharmaceuticals for $12 million) Erytech Pharma SA (NASDAQ: ERYP ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) KITOV PHARMA LT/S ADR (NASDAQ: KTOV ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Neon …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アデュロ・バイオテック ADRO Aduro Biotech Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)